Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: Cabergoline for Prevention of Episodic Migraine
NCT07072910Phase 2Recruiting
- Sponsor
- Aarhus University Hospital
- Start
- Nov 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabergoline in episodic migraine, sponsored by Aarhus University Hospital. Started Nov 2025; status: recruiting.
02
Drugs
cabergoline
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT07072910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07072910.